作者: John L. Ho , Roberto Badaro , Dimitrios Hatzigeorgiou , Steven G. Reed , Warren D. Johnson
DOI: 10.1007/BF01878488
关键词:
摘要: The genusLeishmania, an obligate intramacrophage parasite, causes a wide spectrum of clinical diseases. It is worldwide in distribution and 20 million new cases annually with at risk population approximately 1.5 billion persons. most severe forms are associated high morbidity, mortality relapses conventional therapy. therapeutic issues responses to standard alternative therapies reviewed. Recent developments molecular biology immunology methods employed the study leishmaniasis have defined intricate interaction parasite host immune system. Perturbation may be part survival mechanisms ofLeishmania. In murine model, finding T helper cells that differ by their panel cytokines has allowed more precise definition immunopathogenesis leishmaniasis. Preliminary data from patients lend support this concept altered immunomodulation. Furthermore, enhancement response interferon-γ provided approach for treatment using recombinant disease. Current research early diagnosis, need vaccines reviewed context immunopathology